Protalix BioTherapeutics, Inc. (PLX)

NYSEAMERICAN: PLX · Real-Time Price · USD

2.370

+0.050 (2.16%)

At close: Aug 4, 2026, 4:00 PM EDT

2.370

0.00 (0.00%)

After-hours: Aug 4, 2026, 4:10 PM EDT

Protalix BioTherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	41	14.68	19.76	23.63	17.11	38.99
Short-Term Investments	10.08	15.59	15.07	20.93	5.07	-
Cash & Short-Term Investments	51.08	30.27	34.83	44.56	22.18	38.99
Cash Growth	47.03%	-13.08%	-21.84%	100.90%	-43.11%	1.14%
Accounts Receivable	2.94	8.84	2.91	5.27	4.59	3.44
Inventory	30.47	25.73	21.24	19.05	16.8	17.95
Other Current Assets	1.86	1.83	1.1	1.06	1.31	1.29
Total Current Assets	86.36	66.67	60.08	69.93	44.88	61.67
Net Property, Plant & Equipment	12.95	12.58	10.02	10.88	9.64	9.92
Other Long-Term Assets	3.03	3.09	3.32	3.62	1.27	2.08
Total Assets	102.34	82.35	73.42	84.43	55.79	73.67

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	4.29	5.26	4.53	4.32	5.86	6.99
Accrued Expenses	21.67	19.88	19.59	19.55	12.27	16.43
Current Portion of Long-Term Debt	-	-	-	20.25	-	-
Current Portion of Leases	1.43	1.38	1.5	1.41	1.12	1.21
Unearned Revenue	-	-	-	-	13.18	8.55
Total Current Liabilities	27.39	26.52	25.62	45.53	32.43	33.18
Long-Term Debt	-	-	-	-	28.19	27.89
Long-Term Leases	7.05	6.94	4.03	4.62	4.17	4.38
Other Long-Term Liabilities	0.67	0.66	0.56	0.71	1.64	14.26
Total Long-Term Liabilities	7.72	7.6	4.59	5.34	34	46.53
Total Liabilities	35.11	34.12	30.21	50.87	66.43	79.7

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	-	-	0.08	0.07	0.05	0.05
Additional Paid-in Capital	-	-	421.53	415.05	379.17	368.85
Retained Earnings	-	-	-378.39	-381.55	-389.86	-374.93
Shareholders' Equity	67.23	48.23	43.21	33.57	-10.64	-6.04
Total Liabilities & Equity	102.34	82.35	73.42	84.43	55.79	73.67

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	8.48	8.32	5.53	26.28	33.47	33.47
Net Cash (Debt)	42.6	21.95	29.3	18.28	-11.29	5.52
Net Cash Growth	44.38%	-25.09%	60.31%	-	-	-
Net Cash Per Share	0.53	0.28	0.36	0.22	-0.23	0.13
Book Value	67.23	48.23	43.21	33.57	-10.64	-6.04
Book Value Per Share	0.83	0.61	0.53	0.41	-0.22	-0.14
Tangible Book Value	67.23	48.23	43.21	33.57	-10.64	-6.04
Tangible Book Value Per Share	0.83	0.61	0.53	0.41	-0.22	-0.14

SEC Filings: 10-K · 10-Q